Concepedia
6
Publications
226
Citations
H-Index
2016
Active since
Affiliations
Novo Nordisk (United Kingdom)(Current)
Novo Nordisk (Denmark)
IQVIA (United Kingdom)
Chelsea and Westminster Hospital
G. Vega-Hernández is an author at Novo Nordisk (United Kingdom).
Publications per year
2016–2023
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del
Andrea Lopez, Conor Daly, G. Vega-Hernández et al. · Journal of Cystic Fibrosis · 2023 · 126 citations · Full text
Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
Michael Feher, G. Vega-Hernández, Emina Mocevic et al. · Diabetes Therapy · 2017 · 21 citations · Full text
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes
Michael Feher, John Brazier, Nicolaas C. Schaper et al. · BMJ Open Diabetes Research & Care · 2016 · 20 citations · Full text
Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the <scp>UK</scp> setting
Barnaby Hunt, G. Vega-Hernández, William J. Valentine et al. · Diabetes Obesity and Metabolism · 2017 · 20 citations
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
G. Vega-Hernández, Radek Wojcik, Max Schlueter · Diabetes Therapy · 2017 · 20 citations · Full text
Rows per page
1–5 of 6